We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
This version is made available in accordance with publisher policies. Please cite only the published version using the reference above. Abstract The development of a PET radioligand selective for I 2-imidazoline binding sites (I 2 BS) would enable, for the first time, specific, measurable in vivo imaging of this target protein, along with assessment of(More)
1. Centre for Neuropsychopharmacology, Hammersmith Hospital, Imperial College London, W12 0NN, UK 2. GSK, Global Imaging Unit, Stevenage, SG1 2NY, UK 3. PET Center, Department of Diagnostic Radiology, Yale University, Connecticut, USA 4. Institute of Psychiatry, De Crespigny Park, King’s College London, SE5 8AF, UK 5. Division of Imaging Sciences and(More)
UNLABELLED The development of a PET radioligand selective for I2-imidazoline binding sites (I2BS) would enable, for the first time, specific, measurable in vivo imaging of this target protein, along with assessment of alterations in expression patterns of this protein in disease pathophysiology. METHODS BU99008 was identified as the most promising I2BS(More)
  • 1